Anavex (AVXL) Life Sciences announced the submission of the blarcamesine Marketing Authorization Application, MAA, to the European Medicines Agency, EMA. The MAA submission is for the treatment of Alzheimer’s Disease. Overall, blarcamesine, a small molecule administered orally once daily, demonstrated clinically meaningful improvement over 48 weeks with primary endpoint ADAS-Cog13 score being larger than 2 points. This suggests superior numerical clinical efficacy compared to approved therapies while also slowing neurodegeneration in early AD patients. Blarcamesine’s safety profile indicates not requiring routine MRI monitoring, and the advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and neurodegeneration and could be appealing because of its easy and convenient route of administration and good comparative safety profile.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- D. Boral says Anavex Alzheimer’s approach superior to Cassava
- Anavex announces acceptance of manuscript on blarcamesine Phase IIb/III data
- AVXL Upcoming Earnings Report: What to Expect?
- Largest borrow rate increases among liquid names
- Anavex presents new data from blarcamesine study at CTAD conference